Pivanex AN-9; Pivalyloxymethyl butyrate|cas:122110-53-6|西域试剂

Pivanex AN-9; Pivalyloxymethyl butyrate,95.0%

产品编号：Bellancom-120508| CAS NO：122110-53-6| 分子式：C₁₀H₁₈O₄| 分子量：202.25

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-120508	￥400.00	杭州北京（现货）
Bellancom-120508	￥600.00	杭州北京（现货）
Bellancom-120508	￥1200.00	杭州北京（现货）
Bellancom-120508	￥1800.00	杭州北京（现货）
Bellancom-120508	￥2800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Pivanex AN-9; Pivalyloxymethyl butyrate

产品介绍

Pivanex (AN-9) 是丁酸的衍生物，是口服有效的 HDAC 抑制剂。Pivanex 可下调 bcr-abl 蛋白，增强凋亡 (apoptosis)。Pivanex 具有抗转移和抗血管生成的活性

生物活性

Pivanex (AN-9), a derivative of Butyric acid, is an orally active HDAC inhibitor. Pivanex down-regulates bcr-abl protein and enhances apoptosis. Pivanex has antimetastic and antiangiogenic properties.

体外研究

Pivanex (100-500 μM) exhibits significant anti-proliferation activity in K562 cells.
Pivanex (100-500 μM) also enhances apoptosis and caspase activity in K562 cells.
Pivanex (200 μM) induces enhancement in the G2-M phase, a moderate enhancement in the S phase and a slight reduction in G0-G1 of the cell cycle.
Pivanex (AN-9) has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	K562 cells.
Concentration:	100-500 μM.
Incubation Time:	24 hours.
Result:	Reduced the number of K562 viable cells significantly. 100 μM Pivanex with 0.125 or 0.25 μM STI571 reduced the number of viable cells synergistically.

Apoptosis Analysis

Cell Line:	K562 cells.
Concentration:	100-500 μM.
Incubation Time:	6-72 hours.
Result:	Increased the number of K562 apoptotic cells significantly. Increased the caspase activity in K562 cells significantly after only 4 h of incubation with 500 μM.

体内研究
(In Vivo)

Pivanex (AN9, 200 mg/kg, b.i.d, daily) significantly improves the survival of SMN7 SMA mice. Pivanex (AN9) treatment also marked delays the end stage of disease as defined by the onset of body mass loss.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SMN7 SMA mice (SMN2^+/+; SMN7^+/+; mSmn^−/−).
Dosage:	200 mg/kg.
Administration:	Oral administration, b.i.d, at 09.00 and 17.00 daily.
Result:	Improved the mean lifespan of treated SMN7 SMA mice by 84.6%. Delayed the onset of body mass loss in SMN7 SMA mice by 94.9%.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SMN7 SMA mice (SMN2^+/+; SMN7^+/+; mSmn^−/−).
Dosage:	200 mg/kg.
Administration:	Oral administration, b.i.d, at 09.00 and 17.00 daily.
Result:	Improved the mean lifespan of treated SMN7 SMA mice by 84.6%. Delayed the onset of body mass loss in SMN7 SMA mice by 94.9%.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SMN7 SMA mice (SMN2^+/+; SMN7^+/+; mSmn^−/−).
Dosage:	200 mg/kg.
Administration:	Oral administration, b.i.d, at 09.00 and 17.00 daily.
Result:	Improved the mean lifespan of treated SMN7 SMA mice by 84.6%. Delayed the onset of body mass loss in SMN7 SMA mice by 94.9%.

性状

Liquid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (494.44 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.9444 mL	24.7219 mL	49.4438 mL
5 mM	0.9889 mL	4.9444 mL	9.8888 mL
10 mM	0.4944 mL	2.4722 mL	4.9444 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (12.36 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (12.36 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (12.36 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (12.36 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (12.36 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (12.36 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。